Indivumed Announces New Product: Automated Immunohistochemistry Services for the Drug Discovery and Development Market
Posted on: Thursday, 28 June 2007, 09:00 CDT
WASHINGTON, June 28 /PRNewswire/ -- Indivumed announces the launch of immunohistochemistry (IHC) and in situ hybridization (ISH) laboratory services for the cancer drug discovery and development market. Today, Hartmut Juhl, M.D., Ph.D., Indivumed's CEO, described Indivumed's new IHC and ISH capabilities at a molecular histopathology seminar in London, UK, sponsored in part by Ventana Medical Systems. Ventana, whose technology Indivumed employs, is a market leader in automated systems for IHC and ISH analyses that measure important proteins to target against cancer.
The advantage to the market of Indivumed's IHC services will be the tumor biobank of cancer tissue, to which customers will have access, which Indivumed routinely collects across all cancer types. The standard by which these tissues and corresponding clinical data are collected exceeds the U.S. National Cancer Institute's recently published (June 2007) Best Practices for Biospecimen Resources for tissue and data quality. Access to these high quality tissues at routine IHC costs will produce results that reflect the molecular reality of cancer, thereby benefiting pharmaceutical and biopharmaceutical companies developing cancer drugs.
Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington DC, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.
Indivumed, Inc.
CONTACT: Hartmut Juhl MD PhD, CEO of Indivumed GmbH, +49-40-413383-10,+49-40-413383-14 (fax), juhl@indivumed.com, or Kevin Sullivan, Director,Marketing and Sales of Indivumed, Inc., +1-301-588-4650,sullivan@indivumed.com
Web site: http://www.indivumed.com/
Source: PRNewswire
Related Articles
- Cancer Treatment Services of Casa Grande, Arizona, Begins Treating Cancer Patients Using Fast, Precise RapidArc(TM) Radiotherapy Technology
- Key Challenges and Issues Facing the Cancer Cell Therapy Markets
- The Asia Pacific Internet Access Services Market is Seeing Aggressive Revenue Growth, Largely Due to the on-Going Migration to Broadband Service in the Region
- Increasing Competition Aids in Data Communications Services Market Growth in Mexico
- Increased Outsourcing of Network Functions Spur Growth in North American Managed Telecom Services Markets
- Overture Networks Launches Stretch the Edge Campaign to Support Growing Ethernet Services Market
- Smart Document Solutions' New Cancer Registry Service Makes Short Work of Backlogs
- eNotes Defines Product Strategy As Company to Enter Telemedicine and Health Information Services Market
- IP Solutions to Boost Data Communications Services Market Growth in the Small and Medium Enterprises Segment
- Research and Markets: Major Growth is Anticipated in the Chinese Broadband Internet Access Service Market in 2005
 |
 |
User Comments (0)
RSS Feeds